Clinical Trials
7 trialsNCT06984328 2026-06-02
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
Genmab
Phase 2 Active not recruiting
NCT06880549 2026-05-27
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT05537740 2026-05-20
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Bayer
Phase 1 Active not recruiting
NCT05047094 2026-04-06
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
Alpha Tau Medical LTD.
Phase NA Recruiting
NCT05313243 2025-03-20
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Yale University
Phase 2 Recruiting
NCT03385226 2024-12-09
PORT
University College, London
Phase 2 Active not recruiting
NCT02595866 2024-08-09
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
Phase 1 Completed